Table 1.
Patient demographics and disease characteristics of patients in the NOR-DMARD registry (2007–2016)
| Treatment coursea | |||||
|---|---|---|---|---|---|
| MTX monotherapy | bDMARD monotherapy | bDMARDs + MTX | bDMARDs + other csDMARDs | P valueb | |
| (n = 714) | (n = 396) | (n = 1460) | (n = 208) | ||
| Age, mean (s.d.), years | 55.9 (13.2) | 53.9 (13.1) | 53.4 (14.0) | 52.2 (13.5) | 0.37 |
| Sex, female, n (%) | 477 (66.8) | 318 (80.3) | 1079 (73.9) | 174 (83.7) | <0.001 |
| RA disease duration, median (IQR), years | 0.0 (0.0, 0.3) | 10.1 (3.5, 16.3) | 7.8 (2.6, 16.2) | 8.4 (4.6, 17.3) | 0.030 |
| RF positive, n (%) | 445 (62.3) | 204 (51.5) | 737 (50.5) | 113 (54.3) | 0.36 |
| Anti-CCP positive, n (%) | 452 (63.3) | 180 (45.5) | 685 (46.9) | 101 (48.6) | 0.37 |
| Erosive disease, n (%) | 225 (31.5) | 171 (43.2) | 638 (43.7) | 98 (47.1) | 0.25 |
| TJC28, median (IQR) | 5.0 (2.0, 10.0) | 6.0 (2.0, 13.0) | 5.0 (2.0, 10.0) | 5.0 (2.0, 9.0) | 0.003 |
| SJC28, median (IQR) | 4.0 (2.0, 8.0) | 4.0 (2.0, 8.0) | 4.0 (1.0, 8.0) | 4.0 (2.0, 8.0) | 0.55 |
| DAS28-4(ESR), mean (s.d.) | 4.6 (1.4) | 4.9 (1.5) | 4.5 (1.5) | 4.6 (1.4) | <0.001 |
| mHAQ, mean (s.d.) | 0.6 (0.5) | 0.8 (0.5) | 0.7 (0.5) | 0.7 (0.5) | <0.001 |
| PtGA, mean (s.d.) | 46.0 (24.5) | 57.2 (25.2) | 50.0 (25.7) | 47.4 (24.5) | <0.001 |
| CRP, mg/l, median (IQR) | 8.0 (3.0, 20.5) | 7.0 (3.0, 23.0) | 6.0 (3.0, 17.0) | 6.0 (3.0, 17.0) | 0.18 |
| ESR, mm/h, median (IQR) | 21.0 (11.0, 35.0) | 25.0 (13.0, 37.0) | 20.0 (10.0, 35.0) | 21.0 (11.0, 32.0) | 0.004 |
a
Patients who switched treatments are included in ≥1 treatment course.
b
Overall test of equality among bDMARD groups.
bDMARD: biologic DMARD; csDMARDs: conventional synthetic DMARDs; DAS28-4(ESR): DAS in 28 joints, ESR; IQR: interquartile range; mHAQ: modified Health Assessment Questionnaire; NOR-DMARD: Norwegian DMARD; PtGA: patient global assessment; SJC28: number of joints (out of 28) that are swollen; TJC28: number of joints (out of 28) that are tender.